Corona Remedies shares fall 3% despite 44% jump in Q4 profit; margins contract

Shares of Corona Remedies Ltd. fell over 3% on Tuesday, May 12, after the company reported a 20.2% year-on-year rise in revenue for the March quarter, while margins contracted.

Revenue stood at ₹353.1 crore in Q4FY26, compared to ₹293.7 crore in the year-ago period. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 14.4% to ₹62 crore from ₹54.2 crore, while EBITDA margin narrowed by 80 basis points to 17.6% from 18.5% a year ago.

Adjusted profit after tax rose 43.7% YoY to ₹45.3 crore, while PAT margin expanded 210 basis points to 12.8%.

Also read: Dixon Tech Q4 Results: Softer smartphone volumes to impact topline, margins may narrow

For FY26, the company reported revenue of ₹1,403.2 crore, up 17.3% from ₹1,196.4 crore in FY25. EBITDA increased 22.3% to ₹293.4 crore, while adjusted net profit rose 33.4% to ₹199.4 crore.

Corona Remedies said chronic and sub-chronic therapies contributed 72.3% of total revenue in Q4FY26 and 71.9% in FY26.

During the year, the company acquired the Wokadine brand from Dr. Reddy's Laboratories Ltd.

, marking its entry into the povidone iodine market, and also acquired seven brands from Bayer Zydus to strengthen its infertility portfolio.

Also read: Park Medi World Q4 Results: Stock gives up initial spurt despite revenue growth, margin expansion

The company’s Bhayla manufacturing facility received EAEU-GMP certification in January 2026, marking the entry into Eurasian markets including Russia, Belarus and Kazakhstan.

It also expanded production capacity at the facility by adding 400 million units to tablet and capsule capacity.

Corona Remedies said it remains focused on expanding its presence in chronic therapies and increasing market share in the domestic formulations market through product launches, acquisitions and field force expansion.

Shares of the company were trading 2.84% down at ₹1,706 apiece in Tuesday’s session. The stock has gained 8% in the past month and about 22% year-to-date.